Silexion Therapeutics chooses CRO to aid in Phase 2/3 trials for SIL204 after achieving 97% inhibition rates.A strategic contract research organization (CRO) will aid in advancing towards Phase 2/3 trials after SIL204 showcased groundbreaking inhibition rates of 97%.
